How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

469 results for

Pulmonary Hypertension in Sickle Cell Anemia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

421. Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer

or nursing. Patients with history of priapism (persistant erections) and sickle cell anemia. Patients with a BMI(Body Mass Index) ≥ 35 Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00070148 Locations Layout table for location information United States (...) participation in the study. If required, the PSA should be done within 2 weeks prior to registration. Patients with hypercalcemia, nephrosis or the nephrotic phase of nephritis or uncontrolled hypertension, congestive heart failure, pulmonary edema, unstable angina or Cushing's syndrome. Patients with recent (within 6 months) active thromboembolic disease or recent myocardial infarction (within 3 months of study entry). Systemic anticoagulation: Patients currently on oral anticoagulants (warfarin

2003 Clinical Trials

422. Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

with haemoglobinopathies, e.g. sickle cell anaemia, thalassemia major Any prior history of arterial or venous thrombosis AND two or more of the following risk factors: hereditary thrombophilic disorders (e.g. Factor V Leiden, ATIII deficiency, etc), hormone replacement therapy, systemic contraception (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension or cancer Pre-existing cardiac disease (New York Heart Association (NYHA) Grade III/IV), or arrhythmias known to involve the risk (...) DAIDS [ Time Frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3) ] Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells

2007 Clinical Trials

423. The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease

and Hb show a downward tendency as demonstrated in the patient files and medical history Exclusion Criteria: Presence of clinically significant disease/dysfunction of hepatic, pulmonary, hematological (e.g. sickle cell anaemia, thalassemia, major myelodysplastic syndromes, hemolytic anaemia), neurological, musculo-skeletal, endocrine, gastrointestinal or genitourinary system unrelated to underlying chronic renal failure which in the opinion of the investigator would disqualify the patient from (...) this study Cystic kidney disease Clinical or laboratory evidence of untreated iron, folate or Vitamin B12 deficiency Presence of concomitant malignancy (other than basal cell carcinoma of the skin) Uncontrolled hypertension (i.e. diastolic blood pressure of > 100 mm Hg) History of seizures Administration of medication known to suppress erythropoiesis (e.g. cytotoxic agents, immuno-suppressive) within one month prior to enrolment. Low dose steroid therapy will be permitted Pregnancy or lactation Known

2007 Clinical Trials

424. Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

) scan must be performed to rule out diffuse interstitial fibrosis or alveolitis History of or evidence of left-sided heart disease Having any other disease that is associated with pulmonary hypertension (e.g. sickle cell anemia, schistosomiasis). Having a musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease, which is thought to limit ambulation, or be connected to a machine, which is not portable. Uncontrolled systemic hypertension as evidenced by a systolic blood (...) to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH). Unlike Flolan, Remodulin does not need to be mixed daily and is stable at room temperature, so there is no need for ice packs. In addition, Remodulin is changed every 48hrs, instead of every 12-24 (with ice packs) or every 8 hours (without ice packs) with Flolan. Flolan is given using a type of portable medication pump called the CADD Legacy infusion pump. In this study

2007 Clinical Trials

425. Lansoprazole to Treat Children With Asthma

than 33 weeks gestation or any neonate requiring a significant level of respiratory care, including mechanical ventilation Any major chronic illness, including but not limited to non-skin cancer, cystic fibrosis, bronchiectasis, myelomeningocele, sickle cell anemia, endocrine disease, congenital heart disease, congestive heart failure, stroke, severe hypertension, insulin-dependent diabetes mellitus, kidney failure, liver disorder, immunodeficiency state, significant neuro-developmental delay (...) asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Measured at Weeks 0, 4, 8, 12, 16, 20, 24 ] A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed

2007 Clinical Trials

426. Study of Acid Reflux Therapy for Children With Asthma

than 33 weeks gestation or any neonate requiring a significant level of respiratory care, including mechanical ventilation Any major chronic illness, including but not limited to non-skin cancer, cystic fibrosis, bronchiectasis, myelomeningocele, sickle cell anemia, endocrine disease, congenital heart disease, congestive heart failure, stroke, severe hypertension, insulin-dependent diabetes mellitus, kidney failure, liver disorder, immunodeficiency state, significant neuro-developmental delay (...) asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Measured at Weeks 0, 4, 8, 12, 16, 20, 24 ] A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed

2007 Clinical Trials

427. Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

using an intravenous infusion pump. Exclusion Criteria: Nursing or pregnant woman Have any other type of PAH due to conditions other than noted in the above inclusion criteria, including but not limited to PAH related to thrombotic or embolic disease Have any other disease that is associated with pulmonary hypertension (e.g. sickle cell anemia, schistosomiasis) Changes to chronic PAH therapy (i.e., new therapy added within last 30 days[including but not limited to oxygen, a different category (...) . Condition or disease Intervention/treatment Phase Pulmonary Hypertension Drug: treprostinil sodium Phase 4 Detailed Description: Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading

2006 Clinical Trials

428. Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP

Collaborators: Texas Children's Hospital The Methodist Hospital System Information provided by (Responsible Party): Kathryn Leung, Baylor College of Medicine Study Details Study Description Go to Brief Summary: Patients are being asked to participate in this study because they have severe sickle cell anemia (SCD) with or without the beta thalassemia trait. Sickle cell anemia is an illness where the red blood cells change shape and can clog up blood vessels. This keeps the body from getting the oxygen (...) marrow transplants in patients with sickle cell anemia. Condition or disease Intervention/treatment Phase Sickle Cell Disease Hemoglobin SC Drug: Busulfan Biological: Campath 1H Drug: Cyclophosphamide and MESNA Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 8 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Allogeneic Bone Marrow

2007 Clinical Trials

429. Sickle Cell Disease and Sickle Cell Anaemia

cell disease is very variable: a minority have few complications and their disease is clinically unapparent; a majority have intermediate forms, and another minority have severe complications including sepsis, strokes, recurrent painful episodes, acute chest syndrome, pulmonary hypertension and priapism. [ ] Sickle cell trait [ ] Heterozygotes; there is typically 60% HbA and 40% HbS. Sickle cell trait protects against malaria. Sickle cell trait occurs in approximately 300 million people worldwide (...) dysfunction, which is an independent risk factor for mortality. [ ] Chronic pulmonary disease usually develops in patients older than 30 years. Cor pulmonale may develop. Pulmonary hypertension occurs in about 30% of adults with sickle cell disease and is associated with high rates of leg ulcer, priapism, and renal dysfunction. [ ] Gallstones caused by chronic haemolytic anaemia. Eye: retinopathy, retinal infarcts, retinal haemorrhage and retinal detachment. : alloimmunisation, exposure to possible

2008 Mentor

430. Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

for investigator information Principal Investigator: Steven H Abman, MD Children's Hospital Colorado More Information Go to Layout table for additonal information Responsible Party: Robert Small, INO Therapeutics ClinicalTrials.gov Identifier: Other Study ID Numbers: INOT-31 First Posted: July 11, 2002 Last Update Posted: September 9, 2016 Last Verified: September 2016 Additional relevant MeSH terms: Layout table for MeSH terms Lung Diseases Hypertension, Pulmonary Anemia, Sickle Cell Pulmonary Heart Disease (...) adverse events. Condition or disease Intervention/treatment Phase Pulmonary Hypertension Lung Disease Sickle Cell Disease Cardiac Transplant Lung Transplant Drug: Inhaled Nitric Oxide Phase 2 Detailed Description: This study will help develop a comprehensive home care program using INOmax delivery systems. This study will enroll a limited number of patients (5-7) from several disease categories in order to develop the experience with testing acute and chronic responsiveness to INO therapy

2002 Clinical Trials

431. G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

disease risk prediction score of greater than 10% 10 year coronary heart disease (CHD) risk History of heavy smoking with underlying pulmonary disease History of cerebrovascular disease, transient ischemic attack, or stroke Diagnosis of sickle cell anemia or sickle cell trait (to be screened by hemoglobin (Hbg) electrophoresis) Pregnant or lactating Severe psychiatric illness: mental deficiency sufficiently severe as to make informed consent impossible. Mobilization with G-CSF within 90 days (...) such as rheumatoid arthritis, systemic lupus erythematous History of cancer within the past 5 years excluding basal cell or squamous cell carcinoma of the skin History of any hematologic disorders including thromboembolic disease History of cardiac disease such as uncontrolled hypertension, peripheral vascular disease, myocardial infarction, cardiac arrhythmias or related symptoms such as tachycardia, chest pain, shortness of breath which have required medical intervention or treatment or a Framingham coronary

2004 Clinical Trials

432. Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

than 40% and DLCO greater than 40% for this less toxic regimen. Appropriate cardiology or pulmonary consultations should be considered if the patient has severe cardiac or lung disease at the initiation of therapy. I) Hemoglobinopathies: (a)Sickle Cell Anemia having history of one or more of the following despite treatment with standard therapies such as hydroxyurea: i) 2 or more episodes of acute chest syndrome since age 13 years ii) pulmonary hypertension as measured by tricuspid regurgitant jet (...) to allogeneic stem cell transplantation is a risky procedure. For some non-cancerous conditions, the risks of this procedure outweigh the potential benefits. This protocol is designed to test a new approach to allogeneic stem cell transplantation. It is hoped that this approach will be better suited for patients with non-cancerous blood and bone marrow disorders. Condition or disease Intervention/treatment Phase Sickle Cell Anemia Severe Aplastic Anemia Paroxysmal Nocturnal Hemoglobinuria (PNH) Pure Red

1999 Clinical Trials

433. Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

blood pressure [DBP] less than 50 mm Hg) Uncontrolled systemic hypertension (i.e., SBP greater than 180 mm Hg or DBP greater than 100 mm Hg) Known penile deformities or conditions (e.g., sickle cell anemia, multiple myeloma, leukemia) that may predispose participant to priapism Aspartate aminotransferase (AST), serum glutamic pyruvic transaminase (SGPT), alanine aminotransferase (ALT), or serum glutamic oxaloacetic transaminase (SGOT) greater than three times the upper limit of normal range Kidney (...) . Condition or disease Intervention/treatment Phase Pulmonary Fibrosis Hypertension, Pulmonary Drug: Sildenafil Citrate Other: Placebo Phase 3 Detailed Description: IPF is a disease in which fibrous tissue clogs the lungs. This eventually damages air sacs in the lungs and leads to widespread and permanent scarring of lung tissue. Individuals with IPF may experience breathing difficulties, cough, chest pain, and a decreased exercise capacity. Pulmonary hypertension, which is high blood pressure

2007 Clinical Trials

434. Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

within the past 3 months (90 days) Negative pregnancy test Fertile patients must use effective contraception Weight > 40.0 kg and < 150.0 kg No known hypersensitivity to epoetin alfa, darbepoetin alfa, mammalian-cell derived products, or human albumin No uncontrolled hypertension, defined as systolic blood pressure (BP) ≥ 180 mm Hg and/or diastolic BP ≥ 100 mm Hg, despite medical therapy No pulmonary emboli and/or deep vein thrombosis within the past 12 months Patients actively receiving warfarin (...) 10, 2017 Sponsor: Mayo Clinic Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Mayo Clinic Study Details Study Description Go to Brief Summary: RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer. PURPOSE: This randomized clinical trial is studying four different schedules of epoetin alfa or darbepoetin alfa to compare how well they work

2006 Clinical Trials

435. Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

, uterine bleeding, or other chronic bleeding Planned surgery during the course of the study Significant alcohol use or illicit drug use. Patients with a known hypercoagulable state. Active hematologic disease (e.g. sickle cell anemia, thalassemia, chronic myelogenous leukemia) or malignancy Patients with current seizure disorder or activity Patients who are known to be pregnant History of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 12 months before study entry. Prior superficial (...) Chronic pulmonary disease (FEV 1 < 60% predicted) Renal failure (GFR < 15 ml/min) Hemoglobin < 8 g/dL BMI > 40 Exercise limited by angina, claudication, orthopedic, or neurological diseases. Severe liver dysfunction that is defined by an international normalized ratio > 2.0, not caused by an anticoagulant. Current or recent treatment (within past 6 months) with erythropoietin Erythropoietin level > 100 mU/ml Recent cardiac surgery (< 3 months) Known iron deficiency anemia from chronic GI blood loss

2006 Clinical Trials

436. Endothelial function and arterial stiffness in sickle-thalassemia patients. (PubMed)

Endothelial function and arterial stiffness in sickle-thalassemia patients. Homozygous sickle-cell anemia and beta-thalassemia are characterized by impaired endothelial function, while data on arterial stiffness have hitherto been conflicting. We sought to investigate aortic elastic properties and endothelial function in sickle-thalassemia, which combines molecular and clinical features of the above conditions.Forty-seven sickle-thalassemia patients, younger than 45 years, with preserved left (...) ventricular (LV) function and no history of smoking, systemic or pulmonary hypertension, diabetes mellitus, dyslipidemia or thyroid disease, along with 40 healthy controls were studied. Aortic strain, distensibility and stiffness index were calculated by echocardiographically-obtained aortic root diameters. Brachial artery endothelial function was assessed by ultrasonographic evaluation of flow-mediated dilatation (FMD) and nitrate-mediated dilatation (NMD). Left ventricle was assessed by echocardiography

2007 Atherosclerosis

437. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. (Full text)

Anemia (MSH) Patients' Follow-up Study. Levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) provide such information in patients with idiopathic pulmonary arterial hypertension.To determine the relationship between NT-proBNP levels and severity of pulmonary hypertension and prospective mortality in patients with SCD.NT-proBNP levels were measured in 230 participants in the National Institutes of Health (NIH) Sickle Cell Disease-Pulmonary Hypertension Screening Study (enrollment between (...) N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. Thirty percent of patients with sickle cell disease (SCD) develop pulmonary hypertension, a major risk factor for death in this population. A validated blood biomarker of pulmonary hypertension in SCD could provide important prognostic and diagnostic information and allow the exploration of the prevalence of pulmonary hypertension in participants in the 1996 Multicenter Study of Hydroxyurea in Sickle Cell

2006 JAMA

438. Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension

Posted : July 14, 2006 Last Update Posted : April 5, 2019 Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Information provided by: National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: This study will evaluate new treatments for people who have pulmonary hypertension, or high blood pressure in the lungs, caused by sickle cell anemia or thalassemia. Patients ages 18 and older with a diagnosis of sickle cell disease or thalassemia, who have (...) pressure-and to make sure that the blood pressure does not increase when medication is stopped. Patients whose symptoms have improved as a result of breathing NO may wish to continue with that therapy. Condition or disease Intervention/treatment Phase Pulmonary Hypertension Drug: Nitric Oxide/INP Pulse Delivery Drug: Nitric Oxide/INO Pulse Delivery Phase 1 Detailed Description: Sickle cell anemia is an autosomal recessive disorder and the most common genetic disease affecting African-Americans

2006 Clinical Trials

439. Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?

: Rabin Medical Center Information provided by: Rabin Medical Center Study Details Study Description Go to Brief Summary: Patients with hemolytic disorders (e.g. sickle cell anemia or thalassemia) are known to develop pulmonary hypertension. Hemolysis is where red blood cells are destroyed and their contents released into the circulation. It is thought that these red-cell contents cause constriction and thrombosis of the blood vessels in the lungs. Conversely, it is possible that patients (...) Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension? Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension? - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2007 Clinical Trials

440. Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension

end diastolic pressure > 16 mmHg or LVEF < 40% by MUGA, angiography or echocardiography or LV Shortening Fraction < 22% by echocardiography or Symptomatic coronary disease (demonstrable ischemia). Have any disease other than HIV or connective tissue disease associated with PH (e.g. sickle cell anemia, schistosomiasis). Have active AIDS or tuberculosis. Have musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease thought to limit ambulation, or connected to machine (...) Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>